Transave, Inc. is a New Jersey based biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. Transave is developing products based on its proprietary liposomal technology designed specifically for lung delivery. The company focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases.

Company was acquired by Insmed Inc.